A survey of open questions in adaptive therapy: bridging mathematics and clinical translation
Authors:
Jeffrey West,
Fred Adler,
Jill Gallaher,
Maximilian Strobl,
Renee Brady-Nicholls,
Joel S. Brown,
Mark Robertson-Tessi,
Eunjung Kim,
Robert Noble,
Yannick Viossat,
David Basanta,
Alexander R. A. Anderson
Abstract:
Adaptive therapy is a dynamic cancer treatment protocol that updates (or "adapts") treatment decisions in anticipation of evolving tumor dynamics. This broad term encompasses many possible dynamic treatment protocols of patient-specific dose modulation or dose timing. Adaptive therapy maintains high levels of tumor burden to benefit from the competitive suppression of treatment-sensitive subpopula…
▽ More
Adaptive therapy is a dynamic cancer treatment protocol that updates (or "adapts") treatment decisions in anticipation of evolving tumor dynamics. This broad term encompasses many possible dynamic treatment protocols of patient-specific dose modulation or dose timing. Adaptive therapy maintains high levels of tumor burden to benefit from the competitive suppression of treatment-sensitive subpopulations on treatment-resistant subpopulations. This evolution-based approach to cancer treatment has been integrated into several ongoing or planned clinical trials, including treatment of metastatic castrate resistant prostate cancer, ovarian cancer, and BRAF-mutant melanoma. In the previous few decades, experimental and clinical investigation of adaptive therapy has progressed synergistically with mathematical and computational modeling. In this work, we discuss 11 open questions in cancer adaptive therapy mathematical modeling. The questions are split into three sections: 1) the necessary components of mathematical models of adaptive therapy 2) design and validation of dosing protocols, and 3) challenges and opportunities in clinical translation.
△ Less
Submitted 18 October, 2022;
originally announced October 2022.
Recombination Line vs. Forbidden Line Abundances in Planetary Nebulae
Authors:
Mark Robertson-Tessi,
Donald R. Garnett
Abstract:
Recombination lines (RLs) of C II, N II, and O II in planetary nebulae (PNs) have been found to give abundances that are much larger in some cases than abundances from collisionally-excited forbidden lines (CELs). The origins of this abundance discrepancy are highly debated. We present new spectroscopic observations of O II and C II recombination lines for six planetary nebulae. With these data…
▽ More
Recombination lines (RLs) of C II, N II, and O II in planetary nebulae (PNs) have been found to give abundances that are much larger in some cases than abundances from collisionally-excited forbidden lines (CELs). The origins of this abundance discrepancy are highly debated. We present new spectroscopic observations of O II and C II recombination lines for six planetary nebulae. With these data we compare the abundances derived from the optical recombination lines with those determined from collisionally-excited lines. Combining our new data with published results on RLs in other PNs, we examine the discrepancy in abundances derived from RLs and CELs. We find that there is a wide range in the measured abundance discrepancy Delta(O+2) = log O+2(RL) - log O+2(CEL), ranging from approximately 0.1 dex up to 1.4 dex. Most RLs yield similar abundances, with the notable exception of O II multiplet V15, known to arise primarily from dielectronic recombination, which gives abundances averaging 0.6 dex higher than other O II RLs. We compare Delta(O+2) against a variety of physical properties of the PNs to look for clues as to the mechanism responsible for the abundance discrepancy. The strongest correlations are found with the nebula diameter and the Balmer surface brightness. An inverse correlation of Delta(O+2) with nebular density is also seen. Similar results are found for carbon in comparing C II RL abundances with ultraviolet measurements of C III].
△ Less
Submitted 3 December, 2004;
originally announced December 2004.
